Cencora (COR)

• Market cap: $55.5B
• 1 day: 0.81%
• 5 days: 3.20%
• 1 month: 9.88%
• 3 months: 18.46%
• 6 months: 21.69%
• Year to date: 27.59%
• 1 year: 20.17%
• 5 years: 221.49%
• 10 years: 154.63%
• Sector: Healthcare
• Industry: Medical Distribution

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

91% more first-time investments, than exits

New positions opened: 172 | Existing positions closed: 90

30% more call options, than puts

Call options by funds: $1.2B | Put options by funds: $924M

23% more repeat investments, than reductions

Existing positions increased: 473 | Existing positions reduced: 384

5% more funds holding

Funds holding: 1,144 [Q3] → 1,202 (+58) [Q4]

1.51% more ownership

Funds ownership: 98.55% [Q3] → 100.06% (+1.51%) [Q4]

1% less capital invested

Capital invested by funds: $43.7B [Q3] → $43.5B (-$227M) [Q4]

20% less funds holding in top 10

Funds holding in top 10: 15 [Q3] → 12 (-3) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $251 12% downside
• Avg. target: $278 3% downside
• High target: $301 5% upside

5 analyst ratings

• positive: 2 40%
• neutral: 3 60%
• negative: 0 0%

B of A Securities Michael Funk 33% 1-year accuracy 2 / 6 met price target	1% downside $285	Neutral Maintained	11 Apr 2025
Wells Fargo Stephen Baxter 41% 1-year accuracy 13 / 32 met price target	4% downside $274	Equal-Weight Maintained	14 Mar 2025
Evercore ISI Group John Belton 75% 1-year accuracy 3 / 4 met price target	2% downside $280	Outperform Maintained	6 Feb 2025
Wells Fargo Eric Luebchow 37% 1-year accuracy 16 / 43 met price target	12% downside $251	Equal-Weight Maintained	29 Jan 2025
JP Morgan Lisa Gill 61% 1-year accuracy 14 / 23 met price target	5% upside $301	Overweight Maintained	24 Jan 2025